Buspirone

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Buspirone

Examples of brand names: Bespar [DE]

ATC code: N05BE01

Main use (for orientation): Anxiety

Documented research summary

Direct THC–buspirone pharmacodynamic modulation found in a mouse model. Human studies treat cannabis use disorder and assess abstinence, not pharmacokinetics or standardised simultaneous cannabinoid administration. No clinical exposure factor derived for CBD/THC.

Uncertainties and limitations

Oral buspirone HCl single-ingredient tablet, Remedy Repack/Aurobindo; no identity confusion.

Shared enzymes must not be equated with clinical evidence of an interaction; CBD/THC findings cannot be extrapolated to other cannabinoids.

Separately recorded findings

2 separately recorded findings. Each statement applies to its documented study context.

THC – laboratory and animal studies

Finding ID: B0274

Type of result: Direct preclinical investigation of the pair

Observation: Buspirone attenuated THC-induced catalepsy-like immobility.

Mechanism: 5-HT1A-mediated modulation of THC catalepsy

Study type: Mouse behavioural experiment

Context studied: THC 10 mg/kg i.p., buspirone 0.06/0.1 mg/kg; WAY100635 reversed the blockade.

Clinical interpretation: Not a clinical drug–drug interaction or treatment recommendation

Limitations and uncertainties: Animal model, no human pharmacokinetics; not a general reversal of THC intoxication.

Original sources for this finding: Involvement of 5-hydroxytryptamine1A receptors in Delta9-tetrahydrocannabinol-induced catalepsy-like immobilization in mice. [BMED17022969]

Cannabis, non-standardised composition – clinically investigated

Finding ID: B0275

Type of result: Treatment context; no direct evidence of a drug–drug interaction

Observation: Buspirone showed no advantage in reducing use in the larger study; sex differences were observed.

Mechanism: Cannabis use disorder treatment context, not an isolated pair-specific drug–drug interaction

Study type: RCT in 175 adults, 12 weeks; supplemented by an earlier RCT in 50 people

Context studied: Up to 60 mg/day plus psychosocial intervention; earlier study had an uncertain primary abstinence finding, larger study was negative.

Clinical interpretation: CUD treatment outcome, not pharmacokinetic evidence

Limitations and uncertainties: No standardised cannabinoid co-dose; urinary cannabinoids are a substance-use endpoint, not proof of altered clearance.

Original sources for this finding: Buspirone treatment of cannabis dependence: A randomized, placebo-controlled trial. [BMED26386827]; A placebo-controlled trial of buspirone for the treatment of marijuana dependence. [BMED19699593]

References and access status

[V2_LABEL_D0088] BUSPIRONE HYDROCHLORIDE (BUSPIRONE HYDROCHLORIDE) TABLET [REMEDYREPACK INC.]

Original source / bibliographic reference

Authors: REMEDYREPACK INC.

Year: 2026

Source type: Official US SPL / DailyMed

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[BMED17022969] Involvement of 5-hydroxytryptamine1A receptors in Delta9-tetrahydrocannabinol-induced catalepsy-like immobilization in mice.

Original source / bibliographic reference

Authors: Egashira N, Matsuda T, Koushi E, Mishima K, Iwasaki K, Shoyama Y, Fujiwara M.

Year: 2006

Source type: Publication; title and abstract reviewed

DOI: 10.1016/j.ejphar.2006.08.051

PMID: 17022969

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

DOI – publisher access (access restrictions may apply)

[BMED26386827] Buspirone treatment of cannabis dependence: A randomized, placebo-controlled trial.

Original source / bibliographic reference

Authors: McRae-Clark AL, Baker NL, Gray KM, Killeen TK, Wagner AM, Brady KT, DeVane CL, Norton J.

Year: 2015

Source type: Publication; title and abstract reviewed

DOI: 10.1016/j.drugalcdep.2015.08.013

PMID: 26386827

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

[BMED19699593] A placebo-controlled trial of buspirone for the treatment of marijuana dependence.

Original source / bibliographic reference

Authors: McRae-Clark AL, Carter RE, Killeen TK, Carpenter MJ, Wahlquist AE, Simpson SA, Brady KT.

Year: 2009

Source type: Publication; title and abstract reviewed

DOI: 10.1016/j.drugalcdep.2009.06.022

PMID: 19699593

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility